Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Double HER2 Blocking by Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

NCT03979911 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT03979911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Double HER2 Blocking by Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Unknown status
Start date
January 22, 2019
Completion date
July 22, 2019
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, her-2 gene amplification